Page 5 - 台灣肝癌醫學冬季會手冊-1222-V3_Neat

W elcome Message

Dear TLCA members,

On behalf of the president of Taiwan Liver Cancer Association(TLCA), it is my great honor
and privilege to welcome all of you to【2020 台灣肝癌醫學會教育研討會與 Post-ESMO

Update: From clinical trial to real-world data】 on 2020/12/26-12/27 at 台東馬偕醫院.

As the end of 2020 is being coming, many update results of clinical trials and real-world data
particularly from Taiwan, and most recent ESMO data will be presented in the meeting.

In addition, not only medical oncologist but also more and more TLCA members are being
interested in systemic treatment of HCC, particularly molecular target agent (MTA) and

immuno-therapy (IO). Well-trained knowledge of efficacy and adverse effects and their
managements of TKI and IO are mandatory before practice of these medicines. Therefore, we
encourage TLCA members to participate this meeting and ensure 本會會員全程參與兩天的

議程(包括 12/26, 12/27 兩天簽到、簽退)，方可獲得【台灣肝癌醫學會 2020 年12 月肝癌
標靶與免疫治療課程學習認證】.

TLCA is now strongly established as the premier forum for the exchange of the update and

novel basic and clinical science through transverse and multidisciplinary approach to liver
cancer. Regular annual meeting, single topics meeting, post-graduate courses and education
programs will be held by TLCA in the future. We wish TLCA members being able to update
the knowledge, including many scientific research and trials and consensus or guidelines from

every meeting. Therefore, we sincerely anticipate your participation and interaction in the
coming meeting.

The scientific and local organizing committees have formed a strong foundation for ensuring
the success of this meeting.

We are extremely pleased to see you at 台東 for this important meeting.

With best wishes,

Shi-Ming Lin, MD, President

Taiwan Liver Cancer Association (TLCA)
26 December 2020